Unbound MEDLINE

Net financial benefits of averting HIV infections among people who inject drugs in Urumqi, Xinjiang, Peoples Republic of China (2005-2010).

Abstract

BACKGROUND
To quantify the contribution of locally implemented prevention programmes in contributing to reductions in treatment and care costs by averting HIV infections among those who inject drugs this study calculates net financial benefit of providing harm reduction programmes using information from services being implemented in Urumqi, Xinjiang Uighur Autonomous Region of China ( between 2005 and 2010).
METHODS
Information was collected to assess cost of providing methadone treatment (MMT) and needle and syringe programmes (NSP). HIV incidence was estimated among people who inject drugs (PWID). HIV infections averted were calculated. Net benefit was assessed by estimating costs of providing prevention programmes and comparing these to the costs of providing care.
RESULTS
An estimated 5678 (range 3982-7599) HIV infections were averted between 2005 and 2010 and the net financial benefit of providing harm reduction programmes compared to treatment and care costs for HIV infections averted was USD 4.383 million during the same time period.
CONCLUSION
These results demonstrate the net and accumulating benefit of investing in harm reduction programmes for PWID in Urumqi. The return on investment progressively increased during the time period studied and it is clear that these cost savings will continue to accrue with the continued implementation of HIV prevention interventions in the community that include harm reduction programmes targeted at PWID.

Links

  • PMC Free PDF
  • PMC Free Full Text
  • Publisher Full Text
  • Authors

    Ni MJ, Fu LP, Chen XL, Hu XY, Wheeler K

    Institution

    Xinjiang Uighur Autonomous Regional Centre for Disease Control HIV/AIDS, Urumqi, Xinjiang Uighur Autonomous Region, Peoples' Republic of China. kimwheel@yahoo.com

    Source

    BMC public health 12: 2012 pg 572

    MeSH

    China
    Cost-Benefit Analysis
    HIV Infections
    Harm Reduction
    Humans
    Program Evaluation
    Substance Abuse, Intravenous

    Pub Type(s)

    Journal Article
    Research Support, Non-U.S. Gov't

    Language

    eng

    PubMed ID

    22839738